- 合伙人
- 中国北京、美国旧金山
涉及行业及业务范围：生命科学、 动物健康、消费者医疗保健 、数字健康与健康IT、 医疗科技制药与生物科技、商业战略与定价咨询、客户产品与市场战略、定价与收入管理
Bruce Liu为西蒙顾和中国主管合伙人，负责生命科学领域。
Bruce具有20多年生命科学行业的从业经验，他从事制药相关咨询，为生物科技以及医疗科技企业提供战略咨询，包括但不限于公司战略、新款药品研发调研、药品的上市、市场准入、药品定价、医保准入和谈判以及商业模式的优化与创新等方面的咨询，并且也为组织转型和战略发展提供专业咨询。
Bruce具备跨行业的专业知识，对肿瘤学、免疫学、中枢神经系统、心血管、糖尿病、肾病、呼吸系统、眼科与罕见病以及医疗保健价值链的关键环节都有相关专业洞见。鉴于Bruce对医疗行业的专业知识以及对市场的准确判断，他给客户带来了长远的且具有成效的实操战略成果。
在最新发表的文章中，Bruce在医疗科技准入趋势、医疗保险展望、商业模式创新以及全球医疗战略上都有真知灼见，在行业中具有影响力。
Bruce本科毕业于中国复旦大学生化专业，后获得美国罗切斯特大学分子生物学硕士学位，并取得芝加哥大学的MBA学位。
Bruce is a Partner and Managing Director of China at Simon-Kucher.
Bruce has over 20 years of experience in the life sciences industry. He has advised pharmaceutical majors and biotechnology and medical technology companies on key strategic issues, ranging from corporate strategy and scenario planning to research and development and portfolio plans, new product launches, market access and pricing, reimbursement and tendering, commercial excellence, and innovations as well as organization transformation and change management.
He has experience across diverse therapeutic areas, including oncology, immunology, the central nervous system, cardiovascular, diabetes, nephrology, respiratory, ophthalmology, and rare diseases, and across key segments of the healthcare value chain. Building on his in-depth industry expertise and market insights, Bruce helps clients develop actionable strategies for achieving results with a long-lasting impact.
Bruce is recognized as a thought leader on key industry topics, with recent publications on medtech access trends, reimbursement listing outlooks, business model innovations, and globalization strategy.
Bruce earned his MBA from the University of Chicago, MSc in molecular biology from the University of Rochester, and BSc in biochemistry from Fudan University.